Paxil | Paroxetine 160 Mg Breastfeeding

Breast milk is superior in nutrition, It provides resistance against infections and allergies, It is naturally sterile. Despite all the advantages of breastfeeding some mothers choose to pause the breastfeeding in fear of harmful effects of medicines passing in breast milk. Are you wondering about breastfeeding and using Paxil | Paroxetine 160 Mg ? Know what is Paxil | Paroxetine 160 Mg and how it can affect your breast milk and whether Paxil | Paroxetine 160 Mg is safe for your kid or not.

What is Paxil | Paroxetine 160 Mg used for?


Major Depressive Disorder: PAXIL is indicated for the treatment of major depressive disorder. The efficacy of PAXIL in the treatment of a major depressive episode was established in 6‑week controlled trials of outpatients whose diagnoses corresponded most closely to the DSM‑III category of major depressive disorder (see CLINICAL PHARMACOLOGY: Clinical Trials). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: Change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The effects of PAXIL in hospitalized depressed patients have not been adequately studied. The efficacy of PAXIL in maintaining a response in major depressive disorder for up to 1 year was demonstrated in a placebo‑controlled trial (see CLINICAL PHARMACOLOGY: Clinical Trials). Nevertheless, the physician who elects to use PAXIL for extended periods should periodically re‑evaluate the long‑term usefulness of the drug for the individual patient. Obsessive Compulsive Disorder: PAXIL is indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD) as defined in the DSM‑IV. The obsessions or compulsions cause marked distress, are time‑consuming, or significantly interfere with social or occupational functioning. The efficacy of PAXIL was established in two 12‑week trials with obsessive compulsive outpatients whose diagnoses corresponded most closely to the DSM‑IIIR category of obsessive compulsive disorder (see CLINICAL PHARMACOLOGY: Clinical Trials). Obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego‑dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. Long‑term maintenance of efficacy was demonstrated in a 6‑month relapse prevention trial. In this trial, patients assigned to paroxetine showed a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY: Clinical Trials). Nevertheless, the physician who elects to use PAXIL for extended periods should periodically re‑evaluate the long‑term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Panic Disorder: PAXIL is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM‑IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of PAXIL was established in three 10- to 12‑week trials in panic disorder patients whose diagnoses corresponded to the DSM‑IIIR category of panic disorder (see CLINICAL PHARMACOLOGY: Clinical Trials). Panic disorder (DSM‑IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. Long‑term maintenance of efficacy was demonstrated in a 3‑month relapse prevention trial. In this trial, patients with panic disorder assigned to paroxetine demonstrated a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY: Clinical Trials). Nevertheless, the physician who prescribes PAXIL for extended periods should periodically re‑evaluate the long‑term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Social Anxiety Disorder: PAXIL is indicated for the treatment of social anxiety disorder, also known as social phobia, as defined in DSM‑IV (300.23). Social anxiety disorder is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. The efficacy of PAXIL was established in three 12‑week trials in adult patients with social anxiety disorder (DSM‑IV). PAXIL has not been studied in children or adolescents with social phobia (see CLINICAL PHARMACOLOGY: Clinical Trials). The effectiveness of PAXIL in long-term treatment of social anxiety disorder, i.e., for more than 12 weeks, has not been systematically evaluated in adequate and well‑controlled trials. Therefore, the physician who elects to prescribe PAXIL for extended periods should periodically re‑evaluate the long‑term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Generalized Anxiety Disorder: PAXIL is indicated for the treatment of Generalized Anxiety Disorder (GAD), as defined in DSM‑IV. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of PAXIL in the treatment of GAD was established in two 8‑week placebo‑controlled trials in adults with GAD. PAXIL has not been studied in children or adolescents with Generalized Anxiety Disorder (see CLINICAL PHARMACOLOGY: Clinical Trials). Generalized Anxiety Disorder (DSM‑IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following 6 symptoms: Restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, sleep disturbance. The efficacy of PAXIL in maintaining a response in patients with Generalized Anxiety Disorder, who responded during an 8-week acute treatment phase while taking PAXIL and were then observed for relapse during a period of up to 24 weeks, was demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY: Clinical Trials). Nevertheless, the physician who elects to use PAXIL for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Posttraumatic Stress Disorder: PAXIL is indicated for the treatment of Posttraumatic Stress Disorder (PTSD). The efficacy of PAXIL in the treatment of PTSD was established in two 12-week placebo-controlled trials in adults with PTSD (DSM-IV) (see CLINICAL PHARMACOLOGY: Clinical Trials). PTSD, as defined by DSM-IV, requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response that involves intense fear, helplessness, or horror. Symptoms that occur as a result of exposure to the traumatic event include reexperiencing of the event in the form of intrusive thoughts, flashbacks, or dreams, and intense psychological distress and physiological reactivity on exposure to cues to the event; avoidance of situations reminiscent of the traumatic event, inability to recall details of the event, and/or numbing of general responsiveness manifested as diminished interest in significant activities, estrangement from others, restricted range of affect, or sense of foreshortened future; and symptoms of autonomic arousal including hypervigilance, exaggerated startle response, sleep disturbance, impaired concentration, and irritability or outbursts of anger. A PTSD diagnosis requires that the symptoms are present for at least a month and that they cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. The efficacy of PAXIL in longer-term treatment of PTSD, i.e., for more than 12 weeks, has not been systematically evaluated in placebo-controlled trials. Therefore, the physician who elects to prescribe PAXIL for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).

I am breastfeeding mother and I am using Paxil | Paroxetine 160 Mg. Can it have any bad effect on my kid? Shall I search for better alternative?

Paxil | Paroxetine 160 Mg safe for breastfeeding
Active ingredient in Paxil | Paroxetine 160 Mg is Paroxetine and based on our analysis of Paroxetine it appears that using Paxil | Paroxetine 160 Mg is safe in breastfeeding. Below is analysis of Paroxetine while breastfeeding.

Statement of Manufacturer/Labeler about breastfeeding usage
Nursing: Patients should be advised to notify their physician if they are breastfeeding an infant (see PRECAUTIONS: Nursing Mothers).
Nursing Mothers: Like many other drugs, paroxetine is secreted in human milk, and caution should be exercised when PAXIL is administered to a nursing woman.

Paxil | Paroxetine 160 Mg Breastfeeding Analsys


Paroxetine while Breastfeeding

Safe

CAS Number: 61869-08-7

Excreted in tiny amounts into breast milk. Serum levels of breastfed infants whose mothers are on Paroxetine are usually undetectable or very low. No harm effect has been observed on health and short or long term development of infants. Transient troubles in the early neonatal period like drug withdrawal syndrome among newborn or premature infants with high serum levels as a result of treatment with Paroxetine to the mother during pregnancy have been observed. Paroxetine causes fewer problems related to galactorrhea than other antidepressant drugs Mothers who are treated with antidepressant medicaction are in need of stronger support for a higher risk of early breastfeeding failure.


Paxil | Paroxetine 160 Mg Breastfeeding Analsys - 2


Paroxetine while Breastfeeding

CAS Number: 61869-08-7

Paxil | Paroxetine 160 Mg and breastfeeding

Because of the low levels of paroxetine in breastmilk, amounts ingested by the infant are small and paroxetine has not been detected in the serum of most infants tested. Occasional mild side effects have been reported, especially in the infants of mothers who took paroxetine during the third trimester of pregnancy, but the contribution of the drug in breastmilk is not clear. Most authoritative reviewers consider paroxetine one of the preferred antidepressants during breastfeeding.[1][2][3][4][5] Occasional mild side effects such as insomnia, restlessness and increased crying have ben reported in breastfed infants. Mothers taking an SSRI during pregnancy and postpartum may have more difficulty breastfeeding, although this might be a reflection of their disease state.[6] These mothers may need additional breastfeeding support. Breastfed infants exposed to an SSRI during the third trimester of pregnancy have a lower risk of poor neonatal adaptation than formula-fed infants.


Is Paxil | Paroxetine 160 Mg safe while breastfeeding

What if I already have used Paxil | Paroxetine 160 Mg?

Paxil | Paroxetine 160 Mg is safe in breastfeeding and should not create any health problem for your baby but in case you feel any health issue associated with Paxil | Paroxetine 160 Mg you should contact your doctor or health care provider. Be it pregnancy or lactation you shall keep your doctor informed.


I am nursing mother and my doctor has suggested me to use Paxil | Paroxetine 160 Mg, is it safe?

Definitely, Paxil | Paroxetine 160 Mg is safe in lactation for baby. No wonder your doctor has recommended it.


If I am using Paxil | Paroxetine 160 Mg, will my baby need extra monitoring?

No extra baby monitoring required while mother is using Paxil | Paroxetine 160 Mg


Who can I talk to if I have questions about usage of Paxil | Paroxetine 160 Mg in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week